Sementis
Sementis is an Australian unlisted public biotechnology company based in Adelaide, South Australia, dedicated to the research and development of new vaccines to tackle the world's most challenging diseases. Its mission is to deliver an adaptable vaccine platform for rapidly emerging diseases and high unmet medical needs, including allergies. Founded in 2009, Sementis has developed the SCV platform technology and collaborates with various research institutions and industry partners to advance vaccine development and manufacturing capabilities.
Industries
Nr. of Employees
small (1-50)
Sementis
25 North Terrace, Hackney SA 5069, Australia
Patents
Products
Viral vector vaccine platform
A vaccinia-derived viral vector platform engineered for safety, large antigen payloads, plug-and-play antigen insertion, and suitability for thermostable/solid formulations.
Vaccine candidates (infectious disease and allergy programs)
Preclinical and early-stage vaccine candidates developed using the viral vector platform, including candidates targeting SARS-CoV-2 (COVID-19), Zika, chikungunya, and a peanut allergy immunotherapy program.
Viral vector vaccine platform
A vaccinia-derived viral vector platform engineered for safety, large antigen payloads, plug-and-play antigen insertion, and suitability for thermostable/solid formulations.
Vaccine candidates (infectious disease and allergy programs)
Preclinical and early-stage vaccine candidates developed using the viral vector platform, including candidates targeting SARS-CoV-2 (COVID-19), Zika, chikungunya, and a peanut allergy immunotherapy program.
Services
Industry and academic partnership engagements to co-develop vaccine candidates and advance platform technology.
Process development, analytical development and planning for GMP clinical supply and scale-up of viral vector vaccines.
Preparation of clinical development plans and regulatory strategy to progress vaccine candidates into human trials, in collaboration with drug development consultancies.
Industry and academic partnership engagements to co-develop vaccine candidates and advance platform technology.
Process development, analytical development and planning for GMP clinical supply and scale-up of viral vector vaccines.
Preparation of clinical development plans and regulatory strategy to progress vaccine candidates into human trials, in collaboration with drug development consultancies.
Expertise Areas
- Viral vector vaccine development
- Vaccine formulation and solid-dose technologies
- Vaccine process development and scale-up
- Preclinical immunology and animal challenge models
Key Technologies
- Vaccinia-derived viral vector platform
- Genetic engineering for large transgene payloads
- Suspension cell line manufacturing
- Thermostable and solid-dose vaccine formulations
News & Updates
Sementis was recognized at the 2024 DMTC Annual Conference for its collaboration efforts.
Biotechnology company Sementis appointed Dr Anne Collins as CEO to lead vaccine development and partnerships.
Sementis raised over $5.2 million to develop its viral vector-based Covid-19 vaccine and advance clinical trials.
Sementis is developing a vaccinia-based COVID-19 vaccine to provide long-term immunity and address mutant strains.
The Australian government awarded funding to accelerate Sementis' COVID-19 vaccine development, aiming for efficacy against variants.
Dr Anne Collins received the DMTC Collaboration Award in 2024 for vaccine development efforts.
Sementis was recognized at the 2024 DMTC Annual Conference for its collaboration efforts.
Biotechnology company Sementis appointed Dr Anne Collins as CEO to lead vaccine development and partnerships.
Sementis raised over $5.2 million to develop its viral vector-based Covid-19 vaccine and advance clinical trials.
Sementis is developing a vaccinia-based COVID-19 vaccine to provide long-term immunity and address mutant strains.
The Australian government awarded funding to accelerate Sementis' COVID-19 vaccine development, aiming for efficacy against variants.
Dr Anne Collins received the DMTC Collaboration Award in 2024 for vaccine development efforts.